SCHEMBL2197272

SCHEMBL2197272

COc1ccc(C(=O)NCCN2CCOCC2)cc1C(=O)c1ccc(Nc2c(F)cccc2F)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 2/20 0.56
BCL3 P20749 1/20 0.53
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 1/20 0.51
CYP2D6 P10635 1/20 0.51
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
TSHR P16473 1/20 0.50
KMT2A Q03164 1/20 0.49
ACHE P22303 1/20 0.49
LMNA P02545 1/20 0.49
EPHX2 P34913 3/20 0.47
MAPK8 P45983 1/20 0.47
MAPK10 P53779 1/20 0.47
CCR3 P51677 1/20 0.47
POLB P06746 1/20 0.46
HTR1A P08908 1/20 0.46
MAOA P21397 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199380 0.86 MAPK13 (0.44) ALDH1A1SMN1; SMN2KMT2APOLB
SCHEMBL2197429 0.86 MAPK13 (0.44) SMN1; SMN2KMT2A
SCHEMBL2198484 0.84 POLB (0.46) ALDH1A1SMN1; SMN2KDM4EKMT2APOLB
SCHEMBL2202440 0.83 NPC1 (0.53) CYP2C9ALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL2571138 0.80 MAPT (0.49) ALDH1A1SMN1; SMN2KMT2APOLB
SCHEMBL2198948 0.80 MAPK14 (0.42) ALDH1A1SMN1; SMN2KDM4EKMT2A
SCHEMBL2198769 0.79 MAPK13 (0.49) CYP2C9CYP2C19CYP2D6SMN1; SMN2KMT2A
SCHEMBL2200750 0.79 MAPK13 (0.49) CYP2C9SMN1; SMN2POLBRXFP1
SCHEMBL2200077 0.79 MAPK13 (0.49) ALDH1A1SMN1; SMN2LMNA
SCHEMBL6024057 0.79 MAPK13 (0.41) ALDH1A1SMN1; SMN2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP claimed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 CD274 2324/4885BCL3 844/4885CYP2C9 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.